Anthropic Adds Novartis CEO Vas Narasimhan to Its Board—Here’s Why That Matters

Anthropic just made a board appointment that says a lot about where they think AI is headed next. Vas Narasimhan, the CEO of Novartis and a physician-scientist by training, is joining the company’s Board of Directors. He’s not being elected by shareholders—this one comes from the Long-Term Benefit Trust, the independent body that exists to keep Anthropic honest about its public benefit mission.

For those who haven’t been following Anthropic’s governance structure closely, the Trust is a clever piece of corporate architecture. Its members have no financial stake in the company, which means they’re not incentivized to prioritize quarterly earnings over, say, making sure AI doesn’t accidentally cause harm at scale. With Narasimhan’s appointment, Trust-appointed directors now hold a majority on the board. That’s a meaningful shift—it makes the public benefit mission structurally harder to sideline as the company grows.

Narasimhan is an interesting pick. He’s not a typical tech board member. His background is in medicine and global health—early in his career he worked on HIV/AIDS, malaria, and tuberculosis programs in India, Africa, and South America. He’s also an elected member of the US National Academy of Medicine. At Novartis, he’s overseen the development and approval of more than 35 novel medicines, which is a genuinely impressive stat given how heavily regulated the pharmaceutical industry is.

“Getting powerful new technology to people safely and at scale is what we think about every day at Anthropic. Vas has been doing exactly that for years,” said Daniela Amodei, Anthropic’s co-founder and president. She’s not wrong. The parallels between drug approval and AI deployment are closer than they might seem at first glance. Both involve high-stakes technology, both require rigorous testing before release, and both have the potential to cause real harm if rushed.

Neil “Buddy” Shah, who chairs the Trust, emphasized that Narasimhan has “spent his career stewarding breakthrough science responsibly.” That’s the exact language you’d expect from an organization trying to differentiate itself from the move-fast-and-break-things crowd. Anthropic has always positioned itself as the safety-first AI company, and this appointment reinforces that narrative in a concrete way.

Narasimhan himself said something that stuck with me: “In healthcare, AI is accelerating solutions to some of the hardest scientific challenges, from deepening our understanding of disease biology to designing better medicines.” This is higher than I expected from a standard board appointment quote. He’s clearly thinking about this at a practical level, not just offering platitudes.

The rest of the board is a mix of familiar names—Dario Amodei, Daniela Amodei, Yasmin Razavi, Jay Kreps (Confluent co-founder), Reed Hastings (Netflix co-founder), and Chris Liddell (former Microsoft executive). Adding someone with Narasimhan’s regulatory and scientific credibility balances out the tech-heavy lineup.

This is a smart move. Anthropic is signaling that they’re serious about the healthcare angle, which has always been one of the most promising applications for AI. But they’re also signaling something more fundamental: that they intend to keep their governance structure intact even as the company scales. That’s rare in Silicon Valley, where public benefit missions tend to get quietly abandoned once the money gets big enough.

Whether the Trust can actually maintain that balance long-term remains to be seen, but this appointment is a step in the right direction. Having someone on the board who has navigated FDA approvals and global health crises is a genuinely useful perspective for a company building technology that could reshape medicine.